Download fusidic acid (fyoo-sid-ikas-id) - DavisPlus

Name /bks_53161_deglins_md_disk/fusidicacid
02/25/2014 10:01AM
1
Plate # 0-Composite
pg 1 # 1
Use Cautiously in: OB: Safe use during pregnancy has not been established, po-
Canada-Approved Medicine: This monograph describes a medication approved for
use in Canada by the Therapeutic Products Directorate, a division of Health Canada’s
Health Products and Food Branch. The medication is not approved by the United
States Food and Drug Administration; however, a similar formulation carrying a
different generic or brand name might be available in the U.S.
fusidic acid (fyoo-sid-ik as-id)
tential benefits should be weighed against the possible hazards to the fetus (crosses
the placenta); Lactation: Safe use during breast feeding has not been established
(enters breast milk).
Adverse Reactions/Side Effects
Derm: mild local irritation.
Interactions
Drug-Drug: None noted for topical use.
Fucidin, Fucithalmic
Classification
Therapeutic: anti-infectives
Route/Dosage
Topical (Adults and Children): Apply to affected area 3– 4 times daily.
Ophth (Adults and Children): One drop into conjunctival sac of both eyes every
12 hr for 7 days.
Indications
Topical — Local treatment of primary and secondary bacterial skin infections including impetigo contagiosa, erythrasma and secondary skin infections such as infected wounds/burns. Ophthalmic— Treatment of superficial eye infections.
Action
Inhibits bacterial protein synthesis. Therapeutic Effects: Resolution of localized
bacterial infections. Not active against Gram-negative organisms; active against Staphylococci , Streptococci and Corynebacterium.
NURSING IMPLICATIONS
Assessment
● Inspect involved areas of skin and mucous membranes before and frequently dur-
ing therapy. Increased skin irritation may indicate need to discontinue medication.
Potential Nursing Diagnoses
Pharmacokinetics
Absorption: Unknown.
Distribution: Systemically absorbed drug crosses the placenta and enters breast
Risk for infection (Indications)
Acute pain (Indications)
milk.
● Do not confuse topical product with ophthalmic product.
● Topical: Consult health care professional for proper cleansing technique before
Metabolism and Excretion: Absorbed drug is extensively metabolized.
Half-life: 5– 6 hr.
TIME/ACTION PROFILE
ROUTE
Top
ophth
ONSET
unknown
unknown
PEAK
unknown
unknown
DURATION
6–8 hr
12 hr
Contraindications/Precautions
Contraindicated in: Hypersensitivity to fusidic acid or other components of the
formulation (topical ointment contains lanolin).
⫽ Canadian drug name.
⫽ Genetic Implication.
Implementation
applying medication. Apply small amount to cover affected area completely. Avoid
the use of occlusive wrappings or dressings unless directed by health care professional.
● Ophth: Administer 1 drop into conjunctival sac of both eyes every 12 hours for 7
days. See Appendix D for instructions.
Patient/Family Teaching
● Instruct patient to apply medication as directed for full course of therapy, even if
feeling better. Emphasize the importance of avoiding the eyes.
CAPITALS indicate life-threatening, underlines indicate most frequent.
Strikethrough ⫽ Discontinued.
PDF Page #1
Name /bks_53161_deglins_md_disk/fusidicacid
02/25/2014 10:01AM
Plate # 0-Composite
pg 2 # 2
2
● Advise patient to report increased skin irritation or lack of response to therapy to
PDF Page #2
health care professional.
Evaluation/Desired Outcomes
● Resolution of skin or eye infection.
Why was this drug prescribed for your patient?
䉷 2015 F.A. Davis Company